Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function
Bromberger, S.; Zadorozhna, Y.; Ressler, J. M.; Holzner, S.; Nawrocki, A.; Zila, N.; Springer, A.; Larsen, M. R.; Schossleitner, K.
Show abstract
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. Blood vessels are in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that all clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with Vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with Dabrafenib or Encorafenib. Together, these findings provide insights on the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease 92%
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial 91%
- Longitudinal Metabolomics of Human Plasma Reveals Robust Prognostic Markers of COVID-19 Disease Severity 91%
Similar papers in this journal
Similar papers in this journal
- Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors 95%
- Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress 91%
- Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth 91%
Similar papers in this journal
- Recurring EPHB1 mutations in human cancers alter receptor signalling and compartmentalisation of colorectal cancer cells 93%
- PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma 93%
- Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer 92%
Similar papers in this journal
- Bioluminescent zebrafish transplantation model for drug discovery 93%
- Dual blockade of misfolded alpha-sarcoglycan degradation by bortezomib and givinostat combination 92%
- Proteomic phenotyping of stimulated Müller cells uncovers profound pro-inflammatory signaling and antigen-presenting capacity 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.